Abstract | OBJECTIVE: To determine the response to i.v. anti-D and its comparison with splenectomy as second line therapy in refractory and relapsed cases of ITP, in the Aga Khan University Hospital, Karachi. METHODS: A total of 23 patients with chronic ITP were treated with either anti-D or splenectomy as second line treatment. The patients were assessed for time to achieve a response to second line treatment, duration of response and adverse events. RESULTS: There were 12 patients in the anti-D group and 11 in the splenectomy group. The mean platelet count at presentation was 9,000/cumm. The mean age was 8.9 years and 13.0 years and the male to female ratio was 1:1 and 1:1.2 in anti-D and splenectomy group respectively. 54.5% of the patient in the anti-D group responded compared to 81.8% in the splenectomy group. Median time to achieve a response was 7 days in the anti-D group and 1 day in the splenectomy group. Mean time to relapse was 87.8 days in the anti-D group and 55.4 days in the splenectomy group. No adverse events were recorded for any of the infusions of anti-D and none of the patients had more than 0.5 gm/dl fall in the hemoglobin level following anti-D infusion. CONCLUSION: It was thus concluded that Anti-D is a relatively safe, convenient and effective therapy for chronic ITP and can be used as a splenectomy sparing agent when treatment is clinically indicated.
|
Authors | R Sajid, S N Adil, Z Fadoo, S Sabir, M Khurshid |
Journal | JPMA. The Journal of the Pakistan Medical Association
(J Pak Med Assoc)
Vol. 53
Issue 11
Pg. 537-9
(Nov 2003)
ISSN: 0030-9982 [Print] Pakistan |
PMID | 14738260
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Isoantibodies
- RHO(D) antibody
- Rho(D) Immune Globulin
|
Topics |
- Adolescent
- Child
- Dose-Response Relationship, Drug
- Female
- Humans
- Isoantibodies
- Male
- Pakistan
- Purpura, Thrombocytopenic
(immunology, surgery, therapy)
- Recurrence
- Reproducibility of Results
- Rho(D) Immune Globulin
(therapeutic use)
- Splenectomy
- Treatment Outcome
|